Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Acquires Imaxio's Genomics Business

NEW YORK (GenomeWeb News) – French biopharmaceutical firm Hybrigenics said recently that it has acquired the genomics business of biotech company Imaxio for an undisclosed amount.

Hybrigenics said that it received €1.3 million ($1.8 million) through a private placement from Pradeyrol Development to help finance the deal. Pradeyrol is a majority stakeholder in Imaxio.

Imaxio's genomic business is based in Clermont-Limagne Biopole, France and provides fee-for-service studies with a specialty in extracting and sequencing DNA and RNA. Hybrigenics said that it is one of a few European service providers certified by Agilent Technologies to perform SureSelect target enrichment, comparative genomic hybridization, and microRNA microarray technologies.

The facility is equipped with an Illumina sequencer, Hybrigenics added.

Hybrigenics CEO Remi Delansome said in a statement, "The acquisition of the genomics division of Imaxio gives Hybrigenics a foothold in the booming market of genomic services and the investment by Pradeyrol Development is providing resources to develop this new business. In addition, commercial synergies with Hybrigenics Services' proteomics activities will be fostered."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.